MEDIAN Technologies has been selected to provide its imaging solutions in a phase II clinical trial sponsored by a leading biopharmaceutical company.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions provider in a new phase II clinical trial for a global biopharmaceutical company.
As part of the project, imaging data will be acquired in more than 100 clinical sites located in 14 countries worldwide. Anticipated total enrollment is 300 patients with a forecasted project start by year end.
Project amount is estimated at €1.4 M (eq. $1.8 M) for MEDIAN.
“We are enthusiastic about this success. It provides further proof of our commitment to supply biopharma companies with the leading edge tools, expertise and services needed to increase productivity and improve patients’ lives.” said Fredrik Brag, CEO of MEDIAN Technologies.